TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05994131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN10018
Description: orally taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furmonertinib
Description: orally taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furmonertinib
Description: orally taken once daily
Study: NCT04701346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low SAA diet
Description: Diet with low content of methionine and cysteine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High SAA diet
Description: Diet with high content of methionine and cysteine
Study: NCT05915949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Forxiga 10mg Tab once daily will be given to participants for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lobeglitazone 0.5 mg
Description: Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin + Lobeglitazone
Description: Duvie 0.5mg Tab once daily will be given to participants for 24 weeks.
Study: NCT04914598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ENDOSTAR，cisplatin
Description: After sufficient puncture and drainage or drainage, use Endo® (45mg/time in thoracic cavity, 60mg/time in abdominal cavity) + cisplatin (40mg/time) intracavitary injection, administration on 1, 4, and 7 days, 3 times as a course of treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo , cisplatin
Description: Placebo , cisplatin
Study: NCT04214496

Intervention type: DEVICE
Intervention: Sedline
Description: Intraoperative EEG monitorization
Study: NCT05118620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active bupivacaine 0.375% PENG block
Description: A PENG block with bupivacaine 0.375% and epinephrine will be administered using ultrasound-guidance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo normal saline PENG block
Description: A PENG block with normal saline and epinephrine will be administered using ultrasound-guidance
Study: NCT06283953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trach Plus
Description: The Trach Plus program includes education, social support, and outreach to outpatient care team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trach Plus
Description: The Trach Plus program includes education, social support, and outreach to outpatient care team.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trach Me Home
Description: The Trach Me Home discharge program includes caregiver education, skills training and case management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trach Me Home
Description: The Trach Me Home discharge program includes caregiver education, skills training and case management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trach Me Home
Description: The Trach Me Home discharge program includes caregiver education, skills training and case management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trach Me Home
Description: The Trach Me Home discharge program includes caregiver education, skills training and case management.
Study: NCT04884100

Intervention type: OTHER
Group type: OTHER
Intervention: Validating and improving PPG-based algorithms
Description: Our project aims at validating and improving PPG-based algorithms that were previously developed during the time course of a preceding study mini-Holter, accepted by the CER-VD in 2015. The developed features might help improve our understanding of the physio-pathological expression of cardiac arrhythmias. Indeed, current evidence demonstrates that PPG signals contain rich information on diverse cardiovascular mechanisms and properties
Study: NCT05535374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Feetme Connected Soles
Description: Walk for 10 meters (and 30meters): - By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphonecollection of data by smartphone - By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers). If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Feetme Connected Soles
Description: Walk for 10 meters (and 30meters): - By wearing the European Community (EC) labelled connected soles in patient's shoes, triggered by smartphonecollection of data by smartphone - By being filmed by a camera camera mounted on a tripod (excluding the face) for steps counting (2 observers). If there is a technical problem during the walk test, this one can be performed 1 time again 1 hour after initial test.This is expected to happen very rarely.
Study: NCT00730873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Study: NCT06305052

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk
Description: Premature newborns allocated to the intervention group will receive olfactory and taste stimuli immediately before feeding through an oral/nasal gastric tube.~In the intervention group, the taste stimulus will be carried out through a drop of milk administered directly to the tongue of the premature baby if he is awake, if the newborn is sleeping the milk will be placed on his lips.~The olfactory stimulus will be offered through a drop of milk using a cotton swab, positioned close to the premature baby's nostrils as close as possible without touching them, immediately before the tube diet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: In the control group, the taste stimulus will be done through a drop of double-distilled water on a cotton swab, then administered directly to the tongue of the premature baby if he is awake, however, when he is sleeping, the drop of water will be deposited on his lips. The olfactory stimulus in the control group will be carried out with a drop of double-distilled water using a cotton swab, positioned close to the nostrils as close as possible without touching them, immediately before carrying out the tube diet.
Study: NCT06383650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid
Description: Patients will undergo CT imaging with the use of contrast for diagnosis of BCVI. Patients will be monitored for feasibility outcomes, as well as the development of stroke and bleeding complications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid
Description: Patients will undergo CT imaging with the use of contrast for diagnosis of BCVI. Patients will be monitored for feasibility outcomes, as well as the development of stroke and bleeding complications.
Study: NCT05083845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Same blocks with different local anesthetic volume
Description: Erector spinae plane block with different local anesthetic volumes will be applied to the patients under real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Same blocks with different local anesthetic volume
Description: Erector spinae plane block with different local anesthetic volumes will be applied to the patients under real-time ultrasound guidance.
Study: NCT01882296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSPT_10
Description: AGSPT 10mg for 7days administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSPT_20
Description: AGSPT 20mg for 7days administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGSPT_40
Description: AGSPT 20mg x 2tablet for 7days administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole_20
Description: Pantoprazole 20mg for 7days administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole_40
Description: Pantoprazole 40mg for 7days administration
Study: NCT05471388

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum asprosin
Description: assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum asprosin
Description: assessment of serum asprosin by a commercially available double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit.
Study: NCT01571141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monogin
Description: Gynaecological solution with polyhexamethylene biguanide, pH 4.0
Study: NCT05319496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittently scanned continuous glucose monitor (isCGM)
Description: A wearable sensor the size of 2 stacked quarters, that allows individuals to scan their glucose levels on demand. No fingerstick is required. The device measure interstitial glucose through a filament that is inserted under the skin. The application process is painless, and each sensor lasts 90 days. Sensors can be scanned with certain smart phones. This device is marketed as the FreeStyle Libre 2 glucometer (Abbott Laboratories, IL).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and coaching
Description: Two encounters with a certified diabetes educator, who will assess lifestyle and medications, and provide individualized advice on diet, physical activity, and medication changes to improve glycemic control.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and coaching
Description: Two encounters with a certified diabetes educator, who will assess lifestyle and medications, and provide individualized advice on diet, physical activity, and medication changes to improve glycemic control.
Study: NCT04771013

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymic peptides
Description: 250 mg oral daily dose of lyophilized thymic peptides dissolved in 50 mL of water, administered with an empty stomach.
Study: NCT06129383

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: serratus anterior plane block and pectointercostal plane block in breast surgery
Description: Serratus anterior plane block and pecto intercostal plane block will be performed as a single injection using 0.25% bupivacaine and with the same practitioner.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: serratus anterior plane block and pectointercostal plane block in breast surgery
Description: Serratus anterior plane block and pecto intercostal plane block will be performed as a single injection using 0.25% bupivacaine and with the same practitioner.
Study: NCT04243629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rapid-Acting Insulin
Description: Novorapid or Humalog insulin delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapid-Acting Insulin
Description: Novorapid or Humalog insulin delivered in a basal-bolus manner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (saline) delivered in a basal-bolus manner at a fixed ratio with insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide Acetate
Description: Pramlintide acetate delivered in a basal-bolus manner at a fixed ratio with insulin.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Pancreas
Description: Tandem insulin pump, Dexcom G6 sensor, study smartphone running the iMAP algorithm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas
Description: Tandem insulin pump, Dexcom G6 sensor, study smartphone running the iMAP algorithm.
Study: NCT06203535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: In addition to the standard physical therapy exercise programme (which includes flexibility and balance exercises), twenty individuals with idiopathic chronic fatigue will participate in an aerobic training group and walk for 45 minutes on a treadmill three times a week for two months. The workouts began with a five- to ten-minute warm-up on the treadmill and concluded with an equally extended cool-down. Using the Karvonen method, for exercise intensities range from 60 to 75 percent of heart rate reserve during a 35-minute group cumulative exercise session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: In addition to the standard physical therapy exercise programme (which includes flexibility and balance exercises), twenty individuals with idiopathic chronic fatigue will participate in an aerobic training group and walk for 45 minutes on a treadmill three times a week for two months. The workouts began with a five- to ten-minute warm-up on the treadmill and concluded with an equally extended cool-down. Using the Karvonen method, for exercise intensities range from 60 to 75 percent of heart rate reserve during a 35-minute group cumulative exercise session.
Study: NCT05738746

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pasteurized Akkermansia muciniphila
Description: PAM supplementation; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBO administration; packaging will be given to the subjects every one month during follow-up visits, with the instructions to take one dose every morning on an empty stomach
Study: NCT06455657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast cancer education
Description: Questionnaires and scales will be administered to the participants as a pre-test. Breast cancer education will be provided in groups and their feedback will be received. Reminder training will be repeated 1 month after the training. The survey and scales will be administered to the participants as a posttest 1 month after the second training.
Study: NCT05704400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab Biosimilar ABP 798
Description: Rituximab IV: the dose is standard for pediatric nephrotic syndrome; for dosage between 100 and 250 mg rituximab will be diluted in 100 ml of normal saline and administered at 2 ml/h for the first 30'; 3 ml/h for the second 30'; 6 ml/h for the third 30'; 15 ml/h until the end. For dosage between 260 and 500 mg rituximab will be diluted in 250 ml of normal saline and administered at 6 ml/h for the first 30'; 9 ml/h for the second 30'; 18 ml/h for the third 30'; 36 ml/h until the end. For dosage between 510 and 1000 mg rituximab will be diluted in 500 ml of normal saline and administered at 9 ml/h for the first 30'; thereafter, the infusion rate can be doubled every 30 minutes up to a maximum of 72 ml/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab vials 20 mg 1 ml will be collected to reach the desired dose of 16 mg /Kg, the dose is standard recommend to treat myeloma; diluted in 1000 ml of normal saline and infused at the constant speed of 50 ml/h. This will be reduced in case of cutaneous allergic reactions
Study: NCT05934916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP ( Continuous positive airway pressure)
Description: The enrolled eighty patients were simply randomized into two equal groups: Non-CPAP group and CPAP group using a computer-generated table of random numbers. The group allocation was concealed in sequentially numbered, sealed, and opaque envelopes. Patients were selected from isolation center in Mansoura University hospital,Non-CPAP group will receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020 and CPAP group as in Non-CPAP group plus using CPAP.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen therapy
Description: both groups will receive oxygen

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen therapy
Description: both groups will receive oxygen
Study: NCT05978518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPM Device + Monitoring
Description: Daily device use \& data monitoring leading to symptomology assessment and notification to provider.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: CPM Device
Description: Daily device use
Study: NCT04861844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness training
Description: phone based mindfulness training on 4 consecutive days

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active listening
Description: The active listening intervention script asks the participant to attend by relaxing their body and visualizing themself in various exotic locations and narratives described in the script; it also asks the participant to rate their attention level of various points. The active listening scripts were compiled from National Geographic article excerpts (taken from the public domain)
Study: NCT06366646

Intervention type: OTHER
Group type: OTHER
Intervention: Competency-based intervention
Description: 90 head nurses and their assistants received the competency-based intervention program

Intervention type: OTHER
Group type: OTHER
Intervention: Competency-based intervention
Description: 90 head nurses and their assistants received the competency-based intervention program
Study: NCT05843292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane and Carboplatin
Description: Nab-paclitaxel 100mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.~or Docetaxel 75mg/m2+ Carboplatin AUC5 by intravenous (IV) infusion on day1, every 3 weeks, for 4 cycles.~or Paclitaxel 80mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-term Sintilimab
Description: Sintilimab 200mg by intravenous (IV) infusion on day1, every 3 weeks, for 2 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
Study: NCT06064058

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ghazwan program
Description: 6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin D and magnesium correction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard management
Description: Standard care with NSAIDs and acetaminophen for pain management
Study: NCT05682547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% hyaluronate
Description: 0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
Study: NCT04606901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine/glycopyrrolate
Description: neuromuscular blockade reversal agents

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: neuromuscular blockade reversal agent
Study: NCT05634148

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group
Study: NCT06026241

Intervention type: OTHER
Intervention: Collecting data from the medical record
Description: Patient's socio-demographic data (age, gender, residence), comorbidities, cause of death, date and frequency of care measures/treatments/paraclinical exams received before their death.
Study: NCT05137717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Maribavir tablets
Study: NCT05192317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sollievo Fisiolax
Description: Class IIb Medical Device

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sollievo Fisiolax Placebo
Description: Placebo
Study: NCT06018805

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BMI≥30; Combined Spinal Epidural Anesthesia
Description: Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration ( in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BMI:18,5-24,9; Combined Spinal Epidural Anesthesia
Description: Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
Study: NCT04735068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib Pill
Description: Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Pill
Description: Patients will be treated with B 45 mg two times daily and HCQ 400 mg twice daily beginning on day 1. The dose of HCQ is based on an ongoing Phase 1 trial, and may be modified in a future amendment prior to the first patient enrolled. Efforts will be made to ensure dose homogeneity throughout the trial. Treatment will be administered on an outpatient basis on a 28 day cycle
Study: NCT04678505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3402
Description: MK-3402 administered as a single dose of 100 mg IV infusion on the following dosage days:~Panels A to D: Day 1 Panel E: Day 1 in Periods 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3402
Description: MK-3402 administered as a single dose of 100 mg IV infusion on the following dosage days:~Panels A to D: Day 1 Panel E: Day 1 in Periods 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3402
Description: MK-3402 administered as a single dose of 100 mg IV infusion on the following dosage days:~Panels A to D: Day 1 Panel E: Day 1 in Periods 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3402
Description: MK-3402 administered as a single dose of 100 mg IV infusion on the following dosage days:~Panels A to D: Day 1 Panel E: Day 1 in Periods 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3402
Description: MK-3402 administered as a single dose of 100 mg IV infusion on the following dosage days:~Panels A to D: Day 1 Panel E: Day 1 in Periods 1 and 2